Background
==========

Colorectal cancer (CRC) is a highly lethal cancer with increasing incidence and mortality in China. The high mortality rate is mainly due to its late diagnosis and metastasis \[[@b1-medscimonit-25-7042],[@b2-medscimonit-25-7042]\]. It was reported that the 5-year survival rate of patients diagnosed at the early stage was about 90%, but for those patients with late diagnosis, the survival rate dropped sharply to only 5--10% \[[@b3-medscimonit-25-7042]\], indicating that the treatment can be more effective if CRC is detected early \[[@b4-medscimonit-25-7042].[@b5-medscimonit-25-7042]\]. To improve the early diagnosis rate and reduce the high metastasis rate of CRC, it is critical to screen novel bio-makers for predicting CRC diagnosis and metastasis \[[@b6-medscimonit-25-7042]\].

The Human Genome Project found that only 1--2% of the DNA sequences in the human genome is transcribed to produce mRNAs, and 70--90% of RNAs are transcribed into noncoding RNAs (ncRNAs) \[[@b7-medscimonit-25-7042]\]. Among ncRNAs, long noncoding RNAs (lncRNAs) are longer than 200 nucleotides in length and have no potential to code proteins \[[@b8-medscimonit-25-7042]\]. lncRNA has been studied extensively, and increasing evidence suggests that dysregulated lncRNAs are associated with tumorigenesis, metastasis, and drug resistance \[[@b9-medscimonit-25-7042],[@b10-medscimonit-25-7042]\]. For example, HOX antisense intergenic RNA (HOTAIR), Metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT1), and H19 were found to be upregulated and promote tumor invasion and metastasis by regulating various genes in multiple tumors \[[@b11-medscimonit-25-7042]\]. Hua Shen et al. \[[@b12-medscimonit-25-7042]\] previously identified several differentially expressed lncRNAs in CRC tissues from patients with metastasis compared with those without metastasis from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). We verified those lncRNAs by testing clinical patients' tissues and plasma, and found that the expression of RP11-296E3.2 and LEF1-AS1 were significantly associated with CRC patient metastasis and recurrence. RP11-296E3.2 (ENST00000623685.1_1) is a novel lncRNA located at chr1: 99125944-99126615. To date, few studies have reported the physiological and pathological function of RP11-296E3.2. LEF1-AS1 (lymphoid enhancer-binding factor 1 antisense RNA 1, ENSG00000232021), located at chr4: 109088681-109097586 and was reported to be significantly upregulated and to promote GBM cell malignancy via ERK and Akt/mTOR signaling pathway \[[@b13-medscimonit-25-7042]\]. However, the relationships between these 2 lncRNAs and clinicopathological features of CRC patients are still unknown.

In this study, we examined the levels of RP11-296E3.2 and LEF1-AS1 in the tissues and plasma of CRC. Further analysis focused on their diagnostic potential for predicting CRC progression and metastasis, as well as the correlations between their expression and chemoresistance. Our study demonstrated that LEF1-AS1 was upregulated in CRC cancerous tissues compared with paired noncancerous tissues, while RP11-296E3.2 was downregulated, and both of them were significantly correlated with metastasis of CRC and chemoresistance status, suggesting their potential as diagnostic markers and metastasis predictors for CRC.

Material and Methods
====================

Human CRC samples
-----------------

Before surgery and any other treatment, plasma was collected from CRC patient (n=60, 2 patients' clinical information was incomplete) and matched healthy volunteers (n=34), then stored at −80°C within 2 h. Tumor tissues and paired adjacent non-tumor tissues from 91 histopathologically diagnosed CRC patients without preoperative chemotherapy or radiotherapy were collected at the Huzhou First People's Hospital from December 2016 to February 2018. Upon removal, the respective tissues were frozen immediately with liquid nitrogen immediately after colorectal cancer resection and stored at −80°C. Patient clinical information was summarized at the same time. Tumor stages were determined according to the American Joint Committee on Cancer tumor node metastasis (TNM) staging criteria.

The study was reviewed and approved by the Ethics Committee of Huzhou First People's Hospital and was conducted according to the Ethical Guidelines for Human Genome/Gene Research issued by the Chinese government.

RNA extraction and quality control
----------------------------------

Tissue was dissociated to single-cell suspensions using the gentleMACS Dissociator (MACS, Germany). Total RNA was extracted from CRC and volunteer plasma, CRC, and paired adjacent non-tumor (normal) tissue suspensions using Trizol reagent (Invitrogen, Carlsbad, CA, USA), respectively. RNA integrity was assessed using standard denaturing agarose gel electrophoresis. Total RNA concentration and purity of each sample was measured using a NanoDrop ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA).

RT-qPCR for CRC tissues
-----------------------

Total RNA (0.5 μg) was reverse transcribed using the PrimeScript^®^ RT Master Mix (Perfect Real-Time) (TAKARA, Kusatsu, Japan). qRT-PCR was performed for cDNA using the StepOneTM Real-Time PCR System (Life Technologies, Gaithersburg, MD, USA) and the TB Green^®^ premix Ex TaqTM assay (TAKARA). The PCR program was as follows: pre-denaturation at 95°C for 10 min, 40 cycles of denaturation at 95°C for 15 s, and annealing and elongation at 60°C for 1 min.

The primers used for qRT-PCR detection of RP11-296E3.2 and LEF1-AS1 were as follows:

1.  RP11-296E3.2: Forward, 5′-CCAAGACCCAAGGACAACT-3′,

2.  Reverse, 5′-GAAGGATGGGCAGGAGATG-3′;

3.  LEF1-AS1: Forward, 5′-AAGGACGAGAGAAAAGCAC-3′,

4.  Reverse, 5′-CACACAAAGGGGAAGACC-3′;

5.  GAPDH: Forward, 5′-GCACCGTCAAGGCTGAGAAC-3′,

6.  Reverse, 5′-TGGTGAAGACGCCAGTGGA-3′.

ATP-based tumor chemosensitivity assay (ATP-TCA)
------------------------------------------------

ATP-TCA kit, oxaliplatin (L-OHP), irinotecan, and 5-fluorouracil (5-FU) were purchased from Huzhou Haichuang Biotechnology. Tumor tissues were immediately sent to the laboratory under sterile conditions. The tumor tissues were then cut into small pieces (1.0 mm^3^) and digested by enzyme for 1.5--3.0 h at 37°C. Then, 4 clinical first-line drug combinations (5-FU+L-OHP, 5-FU+ irinotecan, L-OHP+ irinotecan, and 5-FU+L-OHP+ irinotecan) were diluted to 5 test drug concentrations (TDC) (200%, 100%, 50%, 25%, and 12.5%) and added to 10-μL cell suspension. The concentration of 100% TDC was determined by peak plasma concentration (PPC) under the conventional clinical dose according to the manufacturer's protocol \[[@b14-medscimonit-25-7042]\]. Three days later, ATP extraction agent (TCE) was added and the fluorescence reader was used to test the ATP fluorescence intensity of the cell suspension at 560 nm.

The inhibition rate (%) of the 5 TDCs can be calculated by the following equation: $\text{inhibition rate }(\%) = \lbrack 1 - (\text{X} - \text{MI})/(\text{MO} - \text{MI})\rbrack \times 100\%$

1.  Index=500--5 TDCs inhibition rate

2.  X: The fluorescence intensities of cells with drug treatment.

3.  M0: The fluorescence intensities of cells without drug treatment.

4.  MI: The fluorescence intensities of medium without cells and drugs.

It was considered drug-resistant if IC90 \>100% TDC, IC50 \>25% TDC, and Index \>300.

Statistical analysis
--------------------

All experimental data were analyzed using GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA) and SPSS 16.0 software system (IBM Corp., Armonk, NY, USA). The chi-squared test was applied to analyze the differential expression of RP11-296E3.2 and LEF1-AS1 between tumor and adjacent non-tumor tissues, CRC patients' and health volunteers' plasma, and subgroups classified by clinicopathological parameters, respectively. Overall survival (OS) rates and disease-free survival time (DFS) were plotted with the Kaplan-Meier method, and the log-rank test was used to analyze survival curves. *p*\<0.05 was considered to be significant.

Results
=======

Validation of the expression of lncRNA candidates in CRC tissues and plasma
---------------------------------------------------------------------------

We examined the expression level of RP11-296E3.2 and LEF1-AS1 levels in 91 CRC tissue samples and 60 plasma samples. As shown in [Figure 1A and 1B](#f1-medscimonit-25-7042){ref-type="fig"}, RP11-296E3.2 was downregulated in 78.7% (70/89) of CRC tissues compared with the corresponding non-tumor tissues (*p*=0.0143), The positive rate of LEF1-AS1 was 23.1% (21/91) in tissues. LEF1-AS1 expression was upregulated in tissues (*p*=0.0322). RP11-296E3.2 and LEF1-AS1 were both slightly down- or upregulated in plasma compared with healthy volunteers, and the difference was not statistically significant (*p*=0.2765 and *p*=0.1132, respectively) ([Figure 1C, 1D](#f1-medscimonit-25-7042){ref-type="fig"}).

lncRNAs are significantly associated with tumor metastasis
----------------------------------------------------------

Compared with CRC tissues and plasma from patients without metastasis, RP11-296E3.2 was upregulated in metastasis patients' samples (*p*=0.0488 and *p*=0.0331, respectively), and LEF1-AS1 was upregulated in tissues but was not different in plasma (*p*=0.0252 and *p*=0.1862, respectively) ([Supplementary Figure 1A--1D](#s2-medscimonit-25-7042){ref-type="supplementary-material"}). Next, we analyzed the correlations between the expression of lncRNAs and clinicopathological features of CRC patients. As shown in the [Table 1](#t1-medscimonit-25-7042){ref-type="table"}, decreased expression of RP11-296E3.2 in CRC was significantly correlated with age (*p*=0.016), lymph node metastasis (p=0.005), and E-cadherin (E-cad) levels (p=0.030) ([Table 1](#t1-medscimonit-25-7042){ref-type="table"}). The expression of RP11-296E3.2 in plasma was also correlated with E-cad levels (*p*=0.016) ([Supplementary Table 1](#s1-medscimonit-25-7042){ref-type="supplementary-material"}). We did not find any correlations between RP11-296E3.2 and the other clinicopathological features. Immunohistochemical staining (IHC) showed that E-cad was significantly underexpressed in the CRC tissue that expressed high level of RP11-296E3.2, and the morphology of mesentery also had changed ([Supplementary Figure 1E](#s2-medscimonit-25-7042){ref-type="supplementary-material"}).

The expression of LEF1-AS1 in CRC tissues was significantly correlated with lymph node metastasis (*p*=0.022) and Ki67 expression (*p*=0.008), one of the clinical diagnostic markers indicating cell proliferation viability. There were no significant correlations between LEF1-AS1 and other clinicopathological features, including age, sex, and metastasis markers like carcinoembryonic antigen (CEA), CA199, E-cad, and CD44-V6. In addition, the expression of LEF1-AS1 in plasma was correlated with carcinoembryonic antigen (CEA) levels (*p*=0.009) ([Supplementary Table 1](#s1-medscimonit-25-7042){ref-type="supplementary-material"}).

Potential diagnostic and prognostic values of lncRNAs in CRC metastasis
-----------------------------------------------------------------------

To evaluate the potential diagnostic value of metastasis, an ROC curve was plotted for lncRNAs levels in CRC tissues and plasma. In CRC tissues, the area under the ROC curve (AUC) of RP11-296E3.2 was 0.654 (*p*=0.012), and the sensitivity and specificity were 0.674 and 0.609, respectively ([Figure 2A](#f2-medscimonit-25-7042){ref-type="fig"}). In plasma, the AUC of RP11-296E3.2 was 0.663 (*p*=0.032), and the sensitivity and specificity was better than that of CEA (0.690 and 0.621, 0.621 and 0.500, respectively) ([Figure 2B](#f2-medscimonit-25-7042){ref-type="fig"}). When the expression level of RP11-296E3.2 was combined with CEA level (AUC=0.660, *p*=0.038), the AUC increased to 0.722 (*p*=0.004), and the sensitivity and specificity were 0.724 and 0.714, respectively ([Figure 2C](#f2-medscimonit-25-7042){ref-type="fig"}), suggesting RP11-296E3.2 may have utility in CRC metastasis prediction and diagnosis. However, the AUC of LEF1-AS1 was 0.613 (*p*=0.067) in tissues and 0.602 (*p*=0.184) in plasma, indicating LEF1-AS1 was unable to distinguish patients with metastasis from others ([Figure 2A, 2B](#f2-medscimonit-25-7042){ref-type="fig"}).

We performed Kaplan-Meier analysis with log-rank test to determine the prognostic potential for lncRNAs in CRC patients using GEPIA software. The OS and DFS of CRC patients with higher LEF1-AS1 expression levels were significantly shorter (log-rank *p*\<0.01) ([Figure 2D, 2E](#f2-medscimonit-25-7042){ref-type="fig"}). RP11-296E3.2 expression in CRC tissues was not significantly correlated with OS and DFS ([Supplementary Figure 2](#s3-medscimonit-25-7042){ref-type="supplementary-material"}). We assessed the prognostic potential for LEF1-AS1 in metastatic CRC patients using the TCGA database (TCGA, Nature 2012). As shown in [Figure 2F](#f2-medscimonit-25-7042){ref-type="fig"}, the OS of metastatic CRC patients with higher LEF1-AS1 expression levels was shorter (log-rank *p*\<0.05), suggesting LEF1-AS1 may be a prognostic marker for metastatic CRC patients.

High RP11-296E3.2 was significantly correlated with drug resistance
-------------------------------------------------------------------

Extensive studies have proved that metastasis plays a major role in cancer multiple drug resistance (MDR) \[[@b15-medscimonit-25-7042]\]. Therefore, we further explored the relationships between MDR and lncRNAs expression in 20 patients' tissues using an ATP-based tumor chemosensitivity assay (ATP-TCA). As shown in [Table 2](#t2-medscimonit-25-7042){ref-type="table"}, RP11-296E3.2 displayed a statistically significant relationship with colorectal cancer MDR (*p*=0.03). The chemosensitivity profiles of CRC patients are shown in [Table 3](#t3-medscimonit-25-7042){ref-type="table"}, and the type of drug resistance combination was 5-FU+L-OHP.

Discussion
==========

The metastasis of CRC can occur in the early stage, and the 5-year survival rate of patients with metastasis is less than 40% \[[@b16-medscimonit-25-7042]\]. Early diagnosis, metastasis monitoring, and guided treatment for CRC at the early stage would have many social benefits \[[@b17-medscimonit-25-7042]\]. Recent studies have found that lncRNAs participate in various physiological and pathological processes of cancer, such as cell proliferation, invasion, and drug resistance \[[@b18-medscimonit-25-7042]--[@b20-medscimonit-25-7042]\]. In this study, we confirmed that 2 novel lncRNAs -- RP11-296E3.2 and LEF1-AS1 -- were differentially expressed in patients with CRC and was closely associated with tumor metastasis. Further analysis showed that RP11-296E3.2 sensitivity and specificity in diagnosis of CRC metastasis is better than that of CEA, and LEF1-AS1 is a good potential prognosis maker for metastatic CRC patients. In addition, high RP11-296E3.2 expression indicated postoperative drug resistance in CRC patients.

lncRNA can affect tumor invasion and metastasis *by* complex mechanisms, including dysregulated expression levels and regulation of target genes, and thus are considered as the next generation of potential prognosis markers. For example, lncRNA/TP73-AS1 was found to function as a competitive endogenous RNA to sponge miR-194, promoting colorectal cancer cell proliferation, migration, and invasion \[[@b18-medscimonit-25-7042]\]. LINC00961 was reported to serve as a prognostic indicator and a potential therapeutic target for glioma patients \[[@b21-medscimonit-25-7042]\]. SNHG20 was identified as an independent unfavorable prognostic factor of osteosarcoma patients, modulating tumor cell migration and invasion \[[@b22-medscimonit-25-7042]\].

In our study, we found the level of RP11-296E3.2 in CRC tissues without metastasis was lower than in adjacent normal tissues, suggesting that it may act as a tumor suppressor. When compared with CRC without metastasis, RP11-296E3.2 showed higher levels in cases with metastasis, suggesting it may participate in metastasis through some other signal pathway and have a double-edged effect on tumors. The double-edged function of genes has been reported in several studies. For example, DEAD-box RNA helicase 3 (DDX3) either activates Wnt signaling to promote lung cancer progression or acts as a lung cancer suppressor through the MDM2/Slug/E-cadherin pathway \[[@b23-medscimonit-25-7042]\]. The nuclear lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is located in the transcriptional regulatory region of the adjacent gene. It can promote or suppress breast cancer metastasis by activating or inactivating the adjacent pro-metastatic transcription factor TEAD \[[@b24-medscimonit-25-7042]\]. Therefore, we speculate that the dual role of RP11-296E3.2 in CRC proliferation and metastasis might be correlated with differences in time and space. Further research is needed to explain the underlying mechanism.

CEA has been used as a serum biomarker for CRC diagnosis and prognosis for several years, but its sensitivity and specificity in screening for CRC metastasis in a serum is limited \[[@b25-medscimonit-25-7042]\] and its efficacy in predicting prognosis and monitoring CRC patients remains controversial \[[@b26-medscimonit-25-7042]\]. In our study, we found that RP11-296E3.2 had better sensitivity and specificity (0.674 and 0.609, respectively) in diagnosis of CRC metastasis compared with CEA (0.621 and 0.500, respectively) in plasma. When the expression level of plasma RP11-296E3.2 was combined with CEA level, the AUC increased to 0.722, indicating that RP11-296E3.2 is complementary to CEA as a prognostic indicator in metastasis CRC.

LEF1-AS1 was upregulated in colorectal cancer tissues and the overexpression of LEF1-AS1 was also correlated with lymph node metastasis. Since patients were retrospectively included between December 2016 and February 2018 in our study and the follow-up is still ongoing, prognostic data are unavailable. Alternatively, we downloaded TCGA data to analyze the predictive function of RP11-296E3.2 and LEF1-AS1 in tumor prognosis. We found that the OS of metastatic CRC patients with higher LEF1-AS1 expression levels was shorter than that of patients with lower LEF1-AS1 expression levels. In glioblastoma (GBM), Wang et al. proved that LEF1-AS1 expression was significantly upregulated and promoted GBM cell malignancy via ERK and Akt/mTOR signaling pathway \[[@b13-medscimonit-25-7042]\]. Our study and the report from Wang et al. both support that high level of LEF1-AS1 expression in tumor tissues indicates poor prognosis and may be a pivotal biomarker for these diseases. The instability of lncRNA in the blood \[[@b27-medscimonit-25-7042]\] may be the major reason why RP11-296E3.2 and LEF1-AS1 perform differently in plasma *vs.* tissues.

In terms of tumor chemoresistance, lncRNAs have been reported to be associated with the progression of drug resistance. For example, increased lncRNA EBIC expression in ovarian cancer can improve cisplatin resistance though regulating the Wnt/β-catenin signaling pathway \[[@b28-medscimonit-25-7042]\]. lncRNA/CASC9 regulates the MDR1 gene by binding to EZH2 and promoting doxorubicin-resistance in breast cancer \[[@b29-medscimonit-25-7042]\]. In our study, we explored the relationships between MDR and expression of RP11-296E3.2 and LEF1-AS1 in 20 patients using an ATP-based tumor chemosensitivity assay (ATP-TCA). The high level of ATP released shows good cell viability, indicating tumor cells were drug-resistant. We found that a high level of RP11-296E3.2 expression was significantly correlated with colorectal cancer cell MDR (*p*=0.03 and *p*=0.05, respectively).

Conclusions
===========

We showed for the first time that 2 novel lncRNAs expressed in CRC were associated with tumor metastasis. When compared with LEF1-AS1 levels in tissues, RP11-296E3.2 showed higher sensitivity and specificity in diagnosis of CRC metastasis. When combined with CEA level in plasma, the diagnostic ability of RP11-296E3.2 is better. The high level of LEF1-AS1 expression in CRC tissues indicated poor prognosis and short survival time of metastatic CRC patients and may be a pivotal prognostic marker for those diseases. In additional, the molecular mechanism underlying the close relationship between CRC metastasis and LEF1-AS1 and RP11-296E3.2 expression and needs further clarification.

Supplementary Data
==================

###### 

Correlation between lncRNAs expression and clinicopathological features in CRC plasma.

  Clinicopathological factor   Total   RP11-296E3.2   χ^2^   *P* value   LEF1-AS1                                                        χ^2^   *P* value           
  ---------------------------- ------- -------------- ------ ----------- --------------------------------------------------------------- ------ ----------- ------- -----------------------------------------------------------------
  Sex                                                                                                                                                               
   Male                        37      11             26     1.856       0.173                                                           20     17          0.222   0.637
   Female                      21      10             11     10          11                                                                                         
  Age                                                                                                                                                               
   \<60 years                  26      12             14     2.019       0.155                                                           14     12          0.085   0.771
   ≥60 years                   32      9              23     16          16                                                                                         
  Tumor size                                                                                                                                                        
   \<5 cm                      33      12             21     0.056       0.813                                                           18     15          0.115   0.734
   ≥5 cm                       24      8              16     12          12                                                                                         
  Lymph node metastasis                                                                                                                                             
   Presence                    29      14             15     3.658       **0.056**                                                       17     12          1.105   0.293
   Absence                     29      7              22     13          16                                                                                         
  CEA                                                                                                                                                               
   Poor                        13      4              9      0.215       0.643                                                           2      9           6.893   **0.009**[\*\*](#tfn5-medscimonit-25-7042){ref-type="table-fn"}
   Well/moderate               45      17             28     28          17                                                                                         
  Ca199                                                                                                                                                             
   Poor                        53      20             33     0.622       0.430                                                           27     25          0.119   0.730
   Well/moderate               5       1              4      3           2                                                                                          
  E-cad                                                                                                                                                             
   Poor                        31      16             15     5.858       **0.016**[\*](#tfn4-medscimonit-25-7042){ref-type="table-fn"}   15     16          0.234   0.628
   Well/moderate               18      3              15     10          8                                                                                          
  CD44-V6                                                                                                                                                           
   Poor                        40      17             23     1.273       0.259                                                           20     20          0.091   0.763
   Well/moderate               9       2              7      5           4                                                                                          
  Ki67                                                                                                                                                              
   ≥0.7                        34      11             23     0.528       0.467                                                           20     14          1.658   0.198
   \<0.7                       24      10             14     10          14                                                                                         

*P* value less than 0.05;

*P* value less than 0.01.

###### 

RP11-296E3.2 and LEF1-AS1 expression are closely associated with CRC metastasis. (**A--D**) RP11-296E3.2 and LEF1-AS1 expression levels in CRC cancer tissues and plasma with metastasis and paired non-metastasis tumor tissues. The expression is shown as the 2^−ΔΔCt^ value. (**E**) IHC stain showed the E-cad expression and morphology of mesentery changes in CRC tissues with different RP11-296E3.2 expressions.

###### 

Kaplan-Meier analysis for the OS and DFS of CRC patients with different expression levels of RP11-296E3.2. (**A, B**) RP11-296E3.2 expression in CRC tissues showed no significant correlations with OS or DFS.
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![RP11-296E3.2 and LEF1-AS1 expression levels in CRC tissues and plasma. (**A, C**) RP11-296E3.2 and LEF1-AS1 expression levels in CRC cancer tissues and paired adjacent non-tumor tissues. (**B, D**) RP11-296E3.2 and LEF1-AS1 expression levels in CRC patients' and health volunteers' plasma. The expression is shown as the 2^−ΔΔCt^.](medscimonit-25-7042-g001){#f1-medscimonit-25-7042}

![Potential diagnostic and prognostic values of lncRNAs in CRC metastasis. (**A**) The ROC curves of tissues RP11-296E3.2 and LEF1-AS1 for CRC patients with metastasis. (**B, C**) The ROC curves of plasma RP11-296E3.2, LEF1-AS1, and CEA for CRC patients with metastasis. (**D, E**) RNA-seq data from the TCGA database showed that the OS and DFS of patients with high LEF1-AS1 expression level were short. (**F**) The OS of metastasis CRC patients with high LEF1-AS1expression was short.](medscimonit-25-7042-g002){#f2-medscimonit-25-7042}

###### 

Correlation between LncRNAs expression and clinicopathological features in CRC tissues.

  Clinicopathological factor   Total   RP11-296E3.2   χ^2^   *P* value   Total                                                             LEF1-AS1   χ^2^   *P* value           
  ---------------------------- ------- -------------- ------ ----------- ----------------------------------------------------------------- ---------- ------ ----------- ------- -----------------------------------------------------------------
  Sex                                                                                                                                                                            
   Male                        55      11             44     0.005       0.945                                                             55         11     44          0.742   0.820
   Female                      34      7              27     36          10                                                                26                                    
  Age                                                                                                                                                                            
   \<60 years                  37      3              34     5.762       **0.016**[\*](#tfn1-medscimonit-25-7042){ref-type="table-fn"}     38         10     28          0.386   0.535
   ≥60 years                   52      15             37     53          11                                                                42                                    
  Tumor size                                                                                                                                                                     
   \<5 cm                      48      10             38     0.024       0.877                                                             50         11     39          0.072   0.788
   ≥5 cm                       41      8              33     41          10                                                                31                                    
  Lymph node metastasis                                                                                                                                                          
   Presence                    43      14             29     7.844       **0.005**[\*\*](#tfn2-medscimonit-25-7042){ref-type="table-fn"}   45         15     30          5.275   **0.022**[\*](#tfn1-medscimonit-25-7042){ref-type="table-fn"}
   Absence                     46      4              42     46          6                                                                 40                                    
  CEA                                                                                                                                                                            
   Poor                        19      4              15     0.010       0.919                                                             21         4      17          0.169   0.681
   Well/moderate               70      14             56     70          17                                                                56                                    
  Ca199                                                                                                                                                                          
   Poor                        60      12             48     0.006       0.940                                                             61         12     49          1.208   0.172
   Well/moderate               29      6              23     30          9                                                                 21                                    
  E-cad                                                                                                                                                                          
   Poor                        37      13             24     4.698       **0.030**[\*](#tfn1-medscimonit-25-7042){ref-type="table-fn"}     39         10     29          0.159   0.690
   Well/moderate               37      5              32     37          11                                                                26                                    
  CD44-V6                                                                                                                                                                        
   Poor                        60      14             46     0.019       0.889                                                             60         18     42          0.799   0.371
   Well/moderate               16      4              12     16          3                                                                 13                                    
  Ki67                                                                                                                                                                           
   ≥0.7                        55      10             45     0.372       0.542                                                             57         8      49          7.026   **0.008**[\*\*](#tfn2-medscimonit-25-7042){ref-type="table-fn"}
   \<0.7                       34      8              26     34          13                                                                21                                    

*P* value less than 0.05;

*P* value less than 0.01.

###### 

Correlation of LncRNAs expression with MDR.

                       n    RP11-296E3.2   χ^2^   *P* value   LEF1-AS1                                                   χ^2^   *P* value          
  -------------------- ---- -------------- ------ ----------- ---------------------------------------------------------- ------ ----------- ------ ------
  Drug resistance      10   4              6      5.00        0.03[\*](#tfn3-medscimonit-25-7042){ref-type="table-fn"}   4      6           3.81   0.12
  No drug resistance   10   0              10                                                                            1      9                  

*P* value less than 0.05.

###### 

Chemosensitivity profiles of CRC patients.

  Patient number   IC50     IC90     Index   Drug-resistant (yes/no)   Drug-resistant combination
  ---------------- -------- -------- ------- ------------------------- ----------------------------
  1                216.16   67.11    301     Yes                       5-FU+L-OHP
  2                214.00   19.93    155     No                        
  3                218.17   34.54    184     No                        
  4                185.41   45.86    201     No                        
  5                269.95   127.97   311     Yes                       5-FU+L-OHP
  6                236.46   136.10   359     Yes                       5-FU+L-OHP
  7                324.40   174.94   367     Yes                       5-FU+L-OHP
  8                213.65   28.88    182     No                        
  9                218.17   340.54   205     No                        
  10               201.83   12.34    167     No                        
  11               574.10   318.95   410     Yes                       5-FU+L-OHP
  12               123.64   20.37    143     No                        
  13               190.54   47.00    204     No                        
  14               258.17   91.26    309     Yes                       5-FU+L-OHP
  15               368.48   204.71   428     Yes                       5-FU+L-OHP
  16               232.13   88.80    257     No                        
  17               452.04   251.13   386     Yes                       5-FU+L-OHP
  18               898.41   499.12   426     Yes                       5-FU+L-OHP
  19               317.46   103.95   308     Yes                       5-FU+L-OHP
  20               213.14   48.40    223     No                        
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